Literature DB >> 2568651

Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.

M W Jann1, G S Fidone, J M Hernandez, S Amrung, C M Davis.   

Abstract

Plasma antipsychotic concentrations were measured in five patients when their anticonvulsant medications were discontinued. Plasma antipsychotic concentrations increased by two- to five-fold at 4 weeks after cessation. All patients demonstrated either moderate or marked improvement as antipsychotic plasma concentrations increased. Four patients experienced extrapyramidal side effects within 30 days of anticonvulsant discontinuation. Careful monitoring of clinical symptoms, adverse effects, and plasma antipsychotic concentrations is recommended.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568651     DOI: 10.1016/0165-1781(89)90043-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

Review 1.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 2.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Metabolism and excretion of mood stabilizers and new anticonvulsants.

Authors:  T A Ketter; M A Frye; G Corá-Locatelli; T A Kimbrell; R M Post
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 5.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 6.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.